Searchable abstracts of presentations at key conferences in endocrinology

ea0056p856 | Pituitary - Clinical | ECE2018

A first-in-human pharmacokinetic, safety, and tolerability study of pasireotide subcutaneous depot

Tiberg Fredrik , Glantz Susanne , Strandgarden Kerstin , Darstein Christelle , Eisinger Johannes , Tauchmanova Libuse , Breitschaft Astrid

Background: Pasireotide is available in twice-daily subcutaneous (sc) and long-acting intramuscular (im) formulations. Pasireotide sc depot is an investigational extended-release sc formulation designed for improved handling and administration. Results are reported from a Phase I dose-escalating study.Methods: All subjects received a single dose of pasireotide sc (600 μg) and were randomized 12:2:2 to pasireotide sc depot as a single upper-thigh inj...